NanoVibronix Gains Approval For Inclusion Of UroShield Products In NHS Prescription Services' Drug Tariff
Portfolio Pulse from Benzinga Newsdesk
NanoVibronix has received approval for the inclusion of its UroShield products in the National Health Service (NHS) Prescription Services' Drug Tariff. This will allow the products to be prescribed and reimbursed by the NHS.
September 27, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NanoVibronix's UroShield products have been approved for inclusion in the NHS Prescription Services' Drug Tariff, potentially increasing the company's revenue.
The approval of NanoVibronix's UroShield products for inclusion in the NHS Prescription Services' Drug Tariff means that these products can now be prescribed and reimbursed by the NHS. This could lead to an increase in sales and revenue for the company, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100